[NF-kappaB tumorigenesis and drug developement]

Wei-Feng Liu1, Shan-Shan Yu, Yue-Zhong Li

  • 1State Key Laboratory of Microbial Technology, School of Life Science, Shandong University, Jinan 250100, China. weifliu@sdu.edu.cn

Insights

Nuclear Factor kappa B (NF-kappaB) regulates key cellular processes like immunity and apoptosis. This review details NF-kappaB activation pathways and its role in tumorigenesis, offering insights for drug screening.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Immunology

Context:

  • NF-kappaB, a transcription factor family, is crucial for cellular responses.
  • Normally inactive in the cytoplasm, NF-kappaB is released by inhibitor degradation upon cellular stimulation.
  • Its activation impacts immunity, inflammation, cell proliferation, and apoptosis.

Purpose:

  • To review diverse NF-kappaB activation mechanisms, including novel pathways.
  • To detail the IKK-mediated signal transduction pathway for NF-kappaB activation.
  • To discuss NF-kappaB's role in tumorigenesis and its potential in drug screening.

Summary:

  • NF-kappaB activation involves IkappaB degradation, enabling nuclear translocation and gene regulation.
  • Alternative pathways involving lymphotoxin and CD40 ligand are highlighted.
  • The review elaborates on IKK regulation, IkappaB degradation, and NF-kappaB transactivation.

Impact:

  • Provides a comprehensive overview of NF-kappaB signaling.
  • Highlights NF-kappaB's dual role in normal physiology and disease, particularly cancer.
  • Offers insights for developing targeted therapies and drug screening strategies.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...